

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Liqin Sun) Group Art Unit: 1614
Serial No.: 10/648,026)
Filed: August 26, 2003)
For: ACUPOINT PATCH)

)
)
)
)
)
)

DECLARATION OF LIQIN SUN UNDER 37 C.F.R. § 1.132

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. I, Liqin Sun, am the inventor of the invention described in the above-identified patent application. I am also a physician with a background in both Western and Chinese medicine and have been in practice for more than thirty years.

2. A website printout relating to the OCULAX acupoint patch (<http://www.3t-herb.com/html/oculax.html>) reports that “[s]ince January to November of 2002, Oculax has been clinically experimented by 3T Manufacturing (USA) Inc.” I performed the clinical experiments referred to in this document, and was responsible both for treating the patients involved in the study and for gathering the data reported in this document. The cited clinical research was performed by me in the United States.


3. Moreover, the patches used in this clinical research were produced following my invention of the subject matter of the above-identified patent application. Patches of this type were first produced by 3T Manufacturing (USA) Inc. using information provided by me, and information describing such patches was not known to

3T Manufacturing (USA) Inc. prior to my disclosure of such information to 3T Manufacturing (USA) Inc.

4. In the course of performing the clinical research described in the aforementioned website printout, no printed materials concerning the contents or make-up of the acupoint patches used in this research were distributed to patients involved in the research.

I declare under penalty of perjury that the foregoing is true and correct, and that if called to testify thereto, I could and would so testify. All of the data provided and any statements made in this declaration are believed to be true. I further declare that I understand that willful false statements and the like are punishable by fine or imprisonment or both (18 U.S.A. § 1001) and may jeopardize the validity of the application or any patent issuing thereon.

Executed this 17 day of September, 2007, at San Gabriel, California.



Dr. Liqin Sun